Infectex, Qurient deal

Qurient granted Infectex exclusive rights to develop and commercialize preclinical tuberculosis compound Q203 in Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan and Ukraine. Infectex said it plans to begin clinical testing by early 2015 and that the deal could be valued at over $100 million. Qurient declined to disclose additional details, and Infectex could not be reached. ...